Skip to main content
Premium Trial:

Request an Annual Quote

Molecular Devices Pays $11M Cash for Xsira s Transfluor Imaging Technology

NEW YORK, March 10 (GenomeWeb News) - Molecular Devices has acquired Xsira Pharmaceutical's Transfluor Imaging technology assets, the Sunnyvale, Calif.-based biotech tools company said late yesterday. 


Molecular Devices paid $11 million in cash for the technology, which is used for visualizing cellular events and detecting receptor activation. The firm said that the acquisition will strengthen its effort to provide imaging solutions to the drug-discovery market. It plans to begin licensing the technology to customers in the second quarter of 2005.


Xsira Pharmaceuticals, which developed the technology with Duke University, said it will now focus on drug discovery, and said that Molecular Devices will license its Transfluor technology back to its original owner to aid in that effort.


Molecular Devices is in the financial position to make such a purchase. It reported a 43-percent increase in fourth quarter revenues for 2004 in February.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.